Santa Fe, NM and Woburn, MA, January 30, 2006 - Today BioTrove and RxGen PrimaTox Inc. (RxP) announced a collaboration to provide gene expression and SNP assays designed to work equally well in primates and humans, thus bridging the gap between pre-clinical and clinical drug safety analysis. RxP's Tox-Optimum™ gene expression assays include the most toxicologically relevant genes, probes for which have been optimized to work in samples from either humans or non-human primates. The Tox-Optimum™ assays have been designed to work specifically and exclusively on BioTrove's OpenArray™ platform, which allows simultaneous quantitative analysis of several thousand genes by quantitative PCR. RxP will provide the Tox-Optimum™ assays as either stand-alone products, or as a service that utilizes RxP's unique toxicological resources. BioTrove will provide the OpenArray™ platform and will manufacture the Tox-Optimum™ assays to RxP's specifications. RxP will also provide similar assays that measure expression of thousands of other genes highly relevant to drug efficacy that have also been optimized for use in either primates or humans.

"By combining BioTrove's extremely powerful platform technology for gene expression and SNP analysis with RxP's deep experience and unique resources in molecular toxicology, we believe we are in a terrific position to identify the most clinically relevant biomarkers and polymorphisms for drug safety. Under this exclusive agreement with BioTrove, we bring individualized drug safety assessment much closer to reality," said Spencer Farr, Ph.D., CEO of RxP. "We looked long and hard to find a platform that provides the sensitivity and specificity of BioTrove's OpenArray platform. When it comes to gene expression and polymorphism, BioTrove knows how to measure them; when it comes to toxicological relevance, we know what to measure….it's a perfect combination," he added.

"Our strategic collaboration with RxGen creates the opportunity for a leading position in the field of molecular toxicology. Previous work in toxicogenomics primarily utilized hybridization arrays to analyze tens of thousands of rat transcripts in order to build predictive models. RxGen's focus on clinically relevant rat and primate models, along with qPCR validated cross species transcripts, will create a new, high-throughput sample analysis solution for the pharmaceutical research community," said Alan Carter, BioTrove's Chief of Commercial Operations.

About RxGen PrimaTox, Inc. (RxP)

RxP is a molecular drug safety company that focuses on finding and employing drug safety biomarkers for general safety assessment as well as for patient stratification around specific drugs. It employs a combination of 'Tox-omics' tools and advanced computational methods to identify the most informative sets of biomarkers for drug toxicity. It is building the world's first commercially primate-based molecular toxicology database. RxP designs and validates assays for toxicology and provides an array of late-stage pre-clinical and early stage clinical molecular tox services. RxP is a subsidiary of RxGen, Inc., a biotechnology company focused on drug discovery. For more information contact, please visit www.RxGen-PrimaTox.com.

About BioTrove, Inc.

BioTrove, Inc. is a biotechnology platform company focused on advancing life science and drug discovery research by leveraging revolutionary micro- and nano-scale technologies. BioTrove has two core platforms: The OpenArray™ core technology enables applications based on a broadly applicable nano-fluidic solutions for massively parallel, low-volume analysis of genomic, proteomic and cellular samples. RapidFire™ Lead Discovery, an assay development and high throughput screening service, unlocks the value of intractable drug targets. For more information contact, please visit www.biotrove.com.

For more information contact:

RxGen PrimaTox.com
Christopher Stanley
Sales@Rxgen-PrimaTox.com
505-995-4427

BioTrove, Inc.
Alan Carter
acarter@biotrove.com
781-721-3648